Accelerating Drug Discovery from Concept to Clinic

We design, synthesize, and optimize drug candidates with an experienced medicinal chemistry team — transforming promising hits into high-quality lead compounds through rigorous SAR-driven DMTA cycles. Our team combines scientific expertise, innovative synthetic strategies, and computational insights to provide integrated chemistry solutions supporting hit identification, lead optimization, candidate selection, and process development across a wide range of therapeutic areas. By leveraging structure-based design, SAR analysis, and advanced synthetic chemistry, we help clients rapidly advance their drug discovery programs while minimizing development risks.

Comprehensive biological profiling powered by robust biochemical, cellular, and translational assay platforms — from hit identification through candidate selection, with mechanistic depth at every stage. At Ciencia Labs CRO, we develop and execute reliable, reproducible, and customized assays that generate high-quality biological data for informed decision-making throughout the drug development pipeline. We support pharmaceutical, biotechnology, academic, and startup organizations with tailored assay solutions ranging from target validation to mechanism-of-action studies and biomarker evaluation.

AI-driven molecular design and advanced computational modeling that reduces development time and experimental costs — integrating structure-based design, machine learning, and molecular dynamics in one platform. Our computational chemistry team combines advanced molecular modeling, artificial intelligence, and data-driven drug discovery approaches to accelerate the identification and optimization of novel therapeutic candidates, helping reduce discovery timelines and improve success rates throughout drug development.

Comprehensive preclinical efficacy, pharmacokinetic, and safety studies designed to advance candidates toward IND filing and clinical development with rigorous, audit-ready documentation. At Ciencia Labs CRO, we provide integrated in vivo pharmacology services to support the evaluation of therapeutic candidates across multiple disease areas, generating robust efficacy, PK, PD, and safety data that facilitate informed decision-making and reduce development risk.

Tailored chemical synthesis from milligram to multi-gram scale — complex molecules, heterocyclic intermediates, fragment libraries, reference standards, and isotope-labeled compounds with full analytical characterization. At Ciencia Labs CRO, our experienced medicinal and synthetic chemistry team specializes in the design, synthesis, purification, and characterization of complex molecules, novel building blocks, reference standards, and isotopically labeled compounds. From early-stage hit validation to advanced lead optimization, we deliver reliable chemistry solutions that accelerate your research pipeline.

State-of-the-art analytical characterization and purification ensuring the highest standards of compound identity, purity, and quality — with full analytical reports for every batch at every scale. All synthesized compounds undergo comprehensive purification and characterization using the latest instrumentation and ICH-aligned methods to meet the highest research and regulatory standards.

Advancing next-generation cancer therapeutics through targeted therapies, immuno-oncology, and innovative small-molecule drug discovery. At Ciencia Labs CRO, we support oncology research programs from target identification through preclinical development. Our multidisciplinary expertise in cancer biology, medicinal chemistry, computational drug design, and translational pharmacology enables the discovery and optimization of novel anti-cancer therapies, collaborating with pharmaceutical companies, biotechnology startups, academic institutions, and research organizations to accelerate safer and more effective cancer treatments.

Developing innovative therapies for cardiovascular and metabolic disorders through integrated drug discovery, translational research, and preclinical development. At Ciencia Labs CRO, we support the discovery and development of novel therapeutics for cardiovascular and metabolic diseases — addressing heart disease, diabetes, obesity, dyslipidemia, and related metabolic disorders through target-based and phenotypic approaches with validated translational disease models.

Advancing treatments for neurological and psychiatric disorders through integrated drug discovery and translational research. At Ciencia Labs CRO, we support the discovery and development of novel CNS therapeutics — addressing neurodegenerative diseases, pain, neuropsychiatric disorders, and brain disorders through innovative target-based and phenotypic approaches with validated CNS-specific disease models.

Developing effective treatments for bacterial, viral, and fungal infections through innovative drug discovery approaches. At Ciencia Labs CRO, we support the discovery and development of novel anti-infective therapeutics — addressing drug-resistant pathogens, emerging infections, and global infectious disease challenges through target-based, phenotypic, and mechanism-based approaches.

Developing targeted treatments for autoimmune and inflammatory diseases through comprehensive immunology research and drug discovery. At Ciencia Labs CRO, we support the discovery and development of novel immunomodulatory therapeutics — addressing autoimmune disorders, chronic inflammation, and fibrotic diseases through evidence-based research with validated immunological assay platforms and translational disease models.

Providing specialized drug discovery and development support for rare and orphan diseases through precision medicine and genomics-driven approaches. At Ciencia Labs CRO, we support the discovery and development of therapeutics for underserved rare disease patient populations — addressing lysosomal storage disorders, neuromuscular diseases, rare genetic conditions, and pediatric rare diseases through genomics-guided precision approaches and innovative drug discovery strategies.